Market open
Sana Biotechnology/$SANA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
Ticker
$SANA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
328
Website
SANA Metrics
BasicAdvanced
$726M
-
-$1.38
1.45
-
Price and volume
Market cap
$726M
Beta
1.45
52-week high
$12.00
52-week low
$1.52
Average daily volume
12M
Financial strength
Current ratio
4.471
Quick ratio
4.234
Long term debt to equity
29.227
Total debt to equity
32.852
Management effectiveness
Return on assets (TTM)
-31.15%
Return on equity (TTM)
-92.90%
Valuation
Price to book
2.48
Price to tangible book (TTM)
7.83
Price to free cash flow (TTM)
-2.614
Growth
Earnings per share change (TTM)
-3.25%
3-year earnings per share growth (CAGR)
-21.74%
What the Analysts think about SANA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
SANA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SANA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SANA News
AllArticlesVideos
There May Still Be Time to Get in on These 3 Trending Biotechs
MarketBeat·1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Accesswire·2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sana Biotechnology stock?
Sana Biotechnology (SANA) has a market cap of $726M as of January 30, 2025.
What is the P/E ratio for Sana Biotechnology stock?
The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of January 30, 2025.
Does Sana Biotechnology stock pay dividends?
No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Sana Biotechnology dividend payment date?
Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sana Biotechnology?
Sana Biotechnology (SANA) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.